CRISPR Therapeutics AG (CRSP) closed at $41.21 in the latest trading session, marking a -1.44% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.47%.

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $30.00. The company’s ...

CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $91.10. CRISPR Therapeutics ( NASDAQ:CRSP – Get Free Report ) last posted its earnings results on Tuesday, November 5th.

CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $91.10. The firm has a 50-day moving average price of $43.76 and a 200 day moving average price of $47.16.

CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%. Meanwhile ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report) and Roche Holding AG (RHHVF – Research Report). Sarepta ...

Ark Invest purchased shares of CRISPR Therapeutics AG for both its ARK Genomic Revolution ETF ARKG and Ark Innovation ETF ARKK. The ARKG ETF bought 43,467 shares, while the ARKK ETF acquired ...

CRISPR Therapeutics AG (CRSP) stock price is 41.21 and CRISPR Therapeutics AG (CRSP) 10-day simple moving average is 41.52. CRISPR Therapeutics AG (CRSP) stock price is 41.21 and CRISPR ...

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...